Two out of four investigational vaccine candidates by Pfizer Inc. and BioNTech SE received Fast Track designation from FDA.
The web page for the FDA Office of Minority Health and Health Equity is no more.
Pfizer and BioNTech receive FDA Fast Track designation for investigational COVID-19 vaccine candidates
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
Robert F. Kenedy Jr., an antivaccine advocate and President Trump’s MAHA nominee, has cleared a key hurdle to be confirmed as secretary of Health and Human Services.
Isolating science by shutting down communication risks building up silos, stymying scientific innovation and dissemination, and creating a culture that excludes rather than includes.
My entire life I was told to respectfully question anything and everything, because questions equal answers, which provide understanding and thereby comfort—even with the uncomfortable. It’s simply in my DNA.
As the chief scientific officer of the Leukemia & Lymphoma Society for the past eleven years, it has been a privilege to lead a group of scientists that has doled out more than $600 million for cutting-edge hematologic oncology research. These dollars went to more than 1,000 research projects through initiatives like our biomedical research grant programs and LLS’s venture philanthropy, the Therapy Acceleration Program (TAP).
Oncological clinical trials pave the way for better patient outcomes and accelerate critical cancer treatments. Their legacy structure, however, often stands in their own way.
